Pages that link to "Q34236636"
Jump to navigation
Jump to search
The following pages link to Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes (Q34236636):
Displaying 10 items.
- Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system (Q28389419) (← links)
- Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. (Q33819755) (← links)
- New drug targets for type 2 diabetes and the metabolic syndrome (Q34105009) (← links)
- Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus (Q34977225) (← links)
- Peroxisome proliferator-activated receptors and atherosclerosis. (Q37861955) (← links)
- Blocking the peroxisome proliferator-activated receptor (PPAR): an overview. (Q38128537) (← links)
- Clinical relevance of target identity and biology: implications for drug discovery and development (Q38147723) (← links)
- Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes (Q44613028) (← links)
- PPARgamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells (Q44643873) (← links)
- Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress (Q46252831) (← links)